Cognition Therapeutics, Inc. provided consolidated earnings guidance for the year ended December 31, 2023. For the year, the company expected net loss to be approximately $25.6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 USD | +1.54% | +3.12% | +7.03% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.03% | 79.28M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.26% | 21.25B | |
-5.61% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023